SS-31 (Elamipretide): Mitochondrial Cardiolipin Targeting and the State of the Research

What SS-31 is

SS-31, also referred to as elamipretide, MTP-131, or Bendavia, is a synthetic tetrapeptide (a peptide of four amino acids). Reviews describe it as a mitochondria-targeting compound whose structure allows uptake across a range of cell types and selective accumulation at the inner mitochondrial membrane, where it has been reported to bind cardiolipin — a phospholipid characteristic of that membrane. On the basis of this cardiolipin interaction, the literature classifies it as a mitochondrial-targeted antioxidant.

How the research studies it

According to review syntheses, SS-31 has been studied chiefly in the context of mitochondrial dysfunction, with preclinical models spanning heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness. Much of this evidence is preclinical (animal and in vitro), and the reviews frame the compound as an investigational candidate rather than an established therapy.

Human data are more narrowly focused on rare, genetically defined mitochondrial disorders. Randomized, placebo-controlled trials such as MMPOWER-3 (in primary mitochondrial myopathy) and TAZPOWER (in Barth syndrome) have been conducted, the latter including a long open-label extension. The overall clinical evidence base remains limited in size and disease scope, and the study populations are small and specific.

What the strongest research examines

In review syntheses, the most consistently described mechanism is selective binding of cardiolipin in the inner mitochondrial membrane, which has been associated in preclinical work with stabilization of mitochondrial cristae structure, reduced oxidative stress markers, and changes in ATP production. Reviews also summarize reported effects on inflammatory signaling, mitochondrial dynamics, and apoptosis, while noting that these characterizations rest largely on animal and in vitro models.

In the human MMPOWER-3 trial, a phase-3 randomized, double-blind, placebo-controlled study in genetically confirmed primary mitochondrial myopathy, participants received subcutaneous elamipretide or placebo over 24 weeks, with primary endpoints of change in six-minute walk test distance and total fatigue on a symptom assessment. In Barth syndrome, the TAZPOWER 168-week open-label extension reported that elamipretide was well tolerated — injection-site reactions being the most common adverse events — and documented changes from open-label baseline on the six-minute walk test and fatigue scores in a cohort of ten patients, of whom eight reached the week-168 visit. These findings are anchored to small, disease-specific human populations and should be read as such.

What the research does not show

The human evidence identified in this search is limited in scale; larger controlled trials establishing exposure and long-term safety in humans are not yet available.